The importance of synthetic drugs for type 2 diabetes drug discovery

Bibliography

• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
   PubMed Web of Science ®Google Scholar
• Beletate V, El Dib RP, Atallah AN. Zinc supplementation for the prevention of type 2 diabetes mellitus. Cochrane Database Syst Rev 2007(1):CD005525
   Google Scholar
• Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002;55:65-85
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Matsuda A. Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 1997;20:219-20
   PubMed Web of Science ®Google Scholar
• American diabetes association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(Suppl 1):S55-60
   PubMed Web of Science ®Google Scholar
• Sollu M, Banji D, Banji OJF, Kumbala VCS. Appraisal on causes and treatment of diabetes mellitus. Arch Appl Sci Res 2010;2(5):239-60
   Google Scholar
• McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010;363:2339-50
   PubMed Web of Science ®Google Scholar
• Mostafalou S, Abdollahi M. Pesticides and human chronic diseases: evidences, mechanisms, and perspectives. Toxicol Appl Pharmacol 2013;268:157-77
   PubMed Web of Science ®Google Scholar
• Hadjibabaie M, Gholami K, Khalili H, et al. Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic type 2 diabetic patients. Therapy 2006;3:759-64
   Google Scholar
• Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem 2009;17:1783-802
   PubMed Web of Science ®Google Scholar
• Hosseini A, Abdollahi M. Diabetic neuropathy and oxidative stress: therapeutic perspectives. Oxide Med Cell Longev 2013;2013:168039
   PubMedGoogle Scholar
• McLennan SV, Abdollahi M, Twigg SM. Connective tissue growth factor, matrix regulation, and diabetic kidney disease. Curr Opin Nephrol Hypertens 2013;22:85-92
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 2005;59:365-73
   PubMed Web of Science ®Google Scholar
• Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med 2013;369(6):540-8
   PubMed Web of Science ®Google Scholar
• Bastaki S. Diabetes mellitus and its treatment. Int J Diabetes Metab 2005;13:111-34
   Google Scholar
• Salari P, Nikfar S, Abdollahi M. No superiority of exenatide over insulin in diabetic patients in terms of weight reduction or incidence of adverse effects: a meta-analysis. Int J Pharmacol 2011;7:749-56
   Google Scholar
• Freeman JS. The increasing epidemiology of diabetes and review of current treatment algorithms. J Am Osteopath Assoc 2010;110:eS2-6
   PubMedGoogle Scholar
• Monika G, Sarbjot S, Punam G. Dipeptidyl peptidase-4 inhibitors: a new approach in diabetes treatment. Int J Drug Dev Res 2009;1:146-56
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Momtaz S, Abdollahi M. An update on pharmacology of Satureja species; from antioxidant, antimicrobial, antidiabetes and anti-hyperlipidemic to reproductive stimulation. Int J Pharmacol 2010;6(4):454-61
   Google Scholar
• Abdollahi M, Zuki AB, Goh YM, et al. Effects of Momordica charantia on pancreatic histopathological changes associated with streptozotocin-induced diabetes in neonatal rats. Histol Histopathol 2011;26:13-21
   PubMed Web of Science ®Google Scholar
• Badri S, Dashti-Khavidaki S, Lessan-Pezeshki M, Abdollahi M. A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. J Pharm Pharm Sci 2011;14:128-37
   PubMed Web of Science ®Google Scholar
• Farshchi A, Nikfar S, Abdollahi M. Concerns on the use of chromium in type 2 diabetes mellitus; needs to conduct major meta-analysis. Int J Pharmacol 2012;8:472
   Google Scholar
• Ghamarian A, Abdollahi M, Su X, et al. Effect of chicory seed extract on glucose tolerance test (GTT) and metabolic profile in early and late stage diabetic rats. Daru 2012;20:56
   PubMed Web of Science ®Google Scholar
• Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of Iranian medicinal plants useful in diabetes mellitus. Arch Med Sci 2008;4:285-92
   Web of Science ®Google Scholar
• Hasani-Ranjbar S, Larijani B, Abdollahi M. Recent update on animal and human evidences of promising anti-diabetic medicinal plants: a mini-review of targeting new drugs. Asian J Anim Vet Adv 2011;6:1271-5
   Web of Science ®Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83
   PubMed Web of Science ®Google Scholar
• Khanavi M, Taheri M, Rajabi A, et al. Stimulation of hepatic glycogenolysis and inhibition of gluconeogenesis are the mechanisms of antidiabetic effect of Centaurea bruguierana ssp. belangerana. Asian J Anim Vet Adv 2012;7:1166-74
   Web of Science ®Google Scholar
• Noor A, Bansal VS, Vijayalakshmi MA. Current update on anti-diabetic biomolecules from key traditional Indian medicinal plants. Curr Sci 2013;104:721-5
   Web of Science ®Google Scholar
• Sarkhail P, Abdollahi M, Fadayevatan S, et al. Effect of Phlomis persica on glucose levels and hepatic enzymatic antioxidants in streptozotocin-induced diabetic rats. Pharmacogn Mag 2010;6:219-24
   PubMed Web of Science ®Google Scholar
• Nakai M, Sekiguchi F, Obata M, et al. Synthesis and insulin-mimetic activities of metal complexes with 3-hydroxypyridine-2-carboxylic acid. J Inorg Biochem 2005;99:1275-82
   PubMed Web of Science ®Google Scholar
• Sakurai H, Adachi Y. The pharmacology of the insulinomimetic effect of zinc complexes. Biometals 2005;18:319-23
   PubMed Web of Science ®Google Scholar
• Sanghera DK, Blackett PR. Type 2 diabetes genetics: beyond gwas. J Diabetes Metab 2012;3(189):6948
   Google Scholar
• Edelman SV. Type II diabetes mellitus. Adv Intern Med 1998;43:449-500
   PubMedGoogle Scholar
• Mercado MM, McLenithan JC, Silver KD, Shuldiner AR. Genetics of insulin resistance. Curr Diab Rep 2002;2:83-95
   PubMedGoogle Scholar
• Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002;90(5):3-10
   Google Scholar
• Bloomgarden ZT. Insulin resistance: current concepts. Clin Ther 1998;20:216-31
   PubMed Web of Science ®Google Scholar
• Watanabe RM. The genetics of insulin resistance: where's Waldo? Curr Diab Rep 2010;10:476-84
   PubMed Web of Science ®Google Scholar
• Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12
   PubMed Web of Science ®Google Scholar
• Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369(2):145-54
   PubMed Web of Science ®Google Scholar
• Saeidi N, Meoli L, Nestoridi E, et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 2013;341(6144):406-10
   PubMed Web of Science ®Google Scholar
• Das UN. Obesity, metabolic syndrome X, and inflammation. Nutrition 2002;18:430-2
   PubMed Web of Science ®Google Scholar
• Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005;46:2347-55
   PubMed Web of Science ®Google Scholar
• Kroder G, Bossenmaier B, Kellerer M, et al. Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J Clin Invest 1996;97:1471-7
   PubMed Web of Science ®Google Scholar
• Lagathu C, Bastard JP, Auclair M, et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003;311:372-9
   PubMed Web of Science ®Google Scholar
• Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000;106:165-9
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85-96
   PubMed Web of Science ®Google Scholar
• Walker RJ, Anderson NM, Jiang Y, et al. Role of beta-adrenergic receptor regulation of TNF-alpha and insulin signaling in retinal Muller cells. Invest Ophthalmol Vis Sci 2011;52:9527-33
   PubMed Web of Science ®Google Scholar
• Reiter CE, Wu X, Sandirasegarane L, et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006;55:1148-56
   PubMed Web of Science ®Google Scholar
• White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002;283:413-22
   PubMed Web of Science ®Google Scholar
• Khan AH, Pessin JE. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 2002;45:1475-83
   PubMed Web of Science ®Google Scholar
• Sasaoka T, Hori H, Wada T, et al. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes. Diabetologia 2001;44:1258-67
   PubMed Web of Science ®Google Scholar
• Sasaoka T, Wada T, Tsuneki H. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol Ther 2006;112:799-809
   PubMed Web of Science ®Google Scholar
• Wada T, Sasaoka T, Funaki M, et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity. Mol Cell Biol 2001;21:1633-46
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994;94:1543-9
   PubMed Web of Science ®Google Scholar
• Long SD, Pekala PH. Regulation of GLUT4 mRNA stability by tumor necrosis factor-alpha: alterations in both protein binding to the 3' untranslated region and initiation of translation. Biochem Biophys Res Commun 1996;220(3):949-53
   PubMed Web of Science ®Google Scholar
• Bastard JP, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002;87(5):2084-9
   PubMed Web of Science ®Google Scholar
• Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-55
   PubMed Web of Science ®Google Scholar
• Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest 2006;116:1756-60
   PubMed Web of Science ®Google Scholar
• Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne) 2013;4:37
   PubMedGoogle Scholar
• Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-12
   PubMed Web of Science ®Google Scholar
• Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008;29:351-66
   PubMed Web of Science ®Google Scholar
• Xiang AH, Kawakubo M, Trigo E, et al. Declining beta-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care 2010;33:396-401
   PubMed Web of Science ®Google Scholar
• Faghihi T, Radfar M, Barmal M, et al. A randomized, placebo-controlled trial of selenium supplementation in patients with type 2 diabetes: effects on glucose homeostasis, oxidative stress, and lipid profile. Am J Ther 2013; Published online 29 Apr 2013; doi:10.1097/MJT.0b013e318269175f
   Google Scholar
• Navaei-Nigjeh M, Rahimifard M, Pourkhalili N, et al. Multi-organ protective effects of cerium oxide nanoparticle/selenium in diabetic rats: evidence for more efficiency of nanocerium in comparison to metal form of cerium. Asian J Anim Vet Adv 2012;7:605-12
   Web of Science ®Google Scholar
• Tabatabaei-Malazy O, Larijani B, Abdollahi M. A novel management of diabetes by means of strong antioxidants' combination. J Med Hypotheses Ideas 2013;7:25-30
   Google Scholar
• Pourkhalili N, Hosseini A, Nili-Ahmadabadi A, et al. Biochemical and cellular evidence of the benefit of a combination of cerium oxide nanoparticles and selenium to diabetic rats. World J Diabetes 2011;2:204-10
   PubMedGoogle Scholar
• Drews G, Krippeit-Drews P, Dufer M. Oxidative stress and beta-cell dysfunction. Pflugers Arch 2010;460:703-18
   PubMed Web of Science ®Google Scholar
• Abdollahi M, Fooladian F, Emami B, et al. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum Exp Toxicol 2003;22:587-92
   PubMed Web of Science ®Google Scholar
• Astaneie F, Afshari M, Mojtahedi A, et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res 2005;36:376-81
   PubMed Web of Science ®Google Scholar
• Farshchi A, Nikfar S, Seyedifar M, Abdollahi M. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharm Sci 2013;16:99-114
   PubMed Web of Science ®Google Scholar
• Hosseini A, Abdollahi M. It is time to formulate an antioxidant mixture for management of diabetes and its complications: notice for pharmaceutical industries. Int J Pharm 2012;8:60-1
   Web of Science ®Google Scholar
• Kamyab S, Hejrati S, Khanavi M, Mohammadirad A. Hepatic mechanisms of the Walnut antidiabetic effect in mice. Cent Eur J Biol 2010;5:304-9
   Web of Science ®Google Scholar
• Larijani B, Afshari M, Astanehi-Asghari F, et al. Effect of short-term carvedilol therapy on salivary and plasma oxidative stress parameters and plasma glucose level in type II diabetes. Therapy 2006;3:119-23
   Google Scholar
• Milani E, Nikfar S, Khorasani R, et al. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 2005;140:251-5
   PubMed Web of Science ®Google Scholar
• Mohseni Salehi Monfared SS, Larijani B, Abdollahi M. Islet transplantation and antioxidant management: a comprehensive review. World J Gastroenterol 2009;15:1153-61
   PubMed Web of Science ®Google Scholar
• Radfar M, Larijani B, Hadjibabaie M, et al. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 2005;59:302-6
   PubMed Web of Science ®Google Scholar
• Sarkhail P, Rahmanipour S, Fadyevatan S, et al. Antidiabetic effect of Phlomis anisodonta: effects on hepatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes. Pharmacol Res 2007;56:261-6
   PubMed Web of Science ®Google Scholar
• Vosough-Ghanbari S, Rahimi R, Kharabaf S, et al. Effects of Satureja khuzestanica on serum glucose, lipids and markers of oxidative stress in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. Evid Based Complement Alternat Med 2010;7:465-70
   PubMed Web of Science ®Google Scholar
• Bolzano K. Biguanides: reasons for withdrawal of drugs and remaining indications. Acta Med Austriaca 1978;5:85-8
   PubMedGoogle Scholar
• Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978;14:75-87
   PubMed Web of Science ®Google Scholar
• Ansari G, Mojtahedzadeh M, Kajbaf F, et al. How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. Adv Ther 2008;25:681-702
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Morsink LM, Smits MM, Diamant M. Advances in pharmacologic therapies for type 2 diabetes. Curr Atheroscler Rep 2013;15:302
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
   PubMed Web of Science ®Google Scholar
• Cusi K, Consoli A, Defronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-67
   PubMed Web of Science ®Google Scholar
• Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9
   PubMed Web of Science ®Google Scholar
• Del Prato S, Marchetto S, Pipitone A, et al. Metformin and free fatty acid metabolism. Diabetes Metab Rev 1995;11:33-41
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4
   PubMed Web of Science ®Google Scholar
• Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997;273:1107-12
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
   PubMed Web of Science ®Google Scholar
• Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998;12:110-19
   PubMed Web of Science ®Google Scholar
• Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7
   PubMed Web of Science ®Google Scholar
• Sheehan MT. Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res 2003;1:189-200
   PubMedGoogle Scholar
• Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925-7
   PubMed Web of Science ®Google Scholar
• Stolar MW, Hoogwerf BJ, Gorshow SM, et al. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm 2008;14:s2-19
   PubMed Web of Science ®Google Scholar
• Rendell MS, Kirchain WR. Pharmacotherapy of type 2 diabetes mellitus. Ann Pharmacother 2000;34:878-95
   PubMed Web of Science ®Google Scholar
• Bharatam PV, Patel DS, Iqbal P. Pharmacophoric features of biguanide derivatives: an electronic and structural analysis. J Med Chem 2005;48:7615-22
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25:2991-3026
   PubMed Web of Science ®Google Scholar
• Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55:20-7
   PubMed Web of Science ®Google Scholar
• Bryan J, Crane A, Vila-Carriles WH, et al. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des 2005;11:2699-716
   PubMed Web of Science ®Google Scholar
• Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003;17:11-15
   PubMed Web of Science ®Google Scholar
• Perfetti R, Ahmad A. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin. Trends Endocrinol Metab 2000;11:218-23
   PubMed Web of Science ®Google Scholar
• Bak JF, Pedersen O. Gliclazide and insulin action in human muscle. Diabetes Res Clin Pract 1991;14(2):61-4
   Google Scholar
• Pedersen O, Hother-Nielsen O, Bak J, et al. Effects of sulfonylureas on adipocyte and skeletal muscle insulin action in patients with non-insulin-dependent diabetes mellitus. Am J Med 1991;90(6A):22-8
   Google Scholar
• Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy 2004;24:606-20
   PubMed Web of Science ®Google Scholar
• Jasik M. Glimepiride in daily practice. Przegl Lek 2003;60:409-12
   PubMedGoogle Scholar
• Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). Vasc Health Risk Manag 2012;8:463-72
   PubMedGoogle Scholar
• Bijlstra PJ, Lutterman JA, Russel FG, et al. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1996;39:1083-90
   PubMed Web of Science ®Google Scholar
• Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531-7
   PubMed Web of Science ®Google Scholar
• Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044-52
   PubMed Web of Science ®Google Scholar
• Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16
   PubMed Web of Science ®Google Scholar
• Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003;2:401-14
   PubMedGoogle Scholar
• Li J, Tian H, Li Q, et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007;9:558-65
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265-70
   PubMed Web of Science ®Google Scholar
• Hu S, Wang S, Fanelli B, et al. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000;293:444-52
   PubMed Web of Science ®Google Scholar
• McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004;43:97-120
   PubMed Web of Science ®Google Scholar
• Chachin M, Yamada M, Fujita A, et al. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels. J Pharmacol Exp Ther 2003;304:1025-32
   PubMed Web of Science ®Google Scholar
• Campbell IW. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract 2005;59:1218-28
   PubMed Web of Science ®Google Scholar
• Spencer CM, Markham A. Troglitazone. Drugs 1997;54:89-101
   PubMed Web of Science ®Google Scholar
• Bae MA, Rhee H, Song BJ. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 2003;139:67-75
   PubMed Web of Science ®Google Scholar
• Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93
   PubMed Web of Science ®Google Scholar
• Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354-61
   PubMed Web of Science ®Google Scholar
• Picard F, Auwerx J. PPAR (gamma) and glucose homeostasis. Annu Rev Nutr 2002;22:167-97
   PubMed Web of Science ®Google Scholar
• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487-91
   PubMed Web of Science ®Google Scholar
• Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15
   PubMed Web of Science ®Google Scholar
• Park KS, Ciaraldi TP, Abrams-Carter L, et al. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. J Clin Endocrinol Metab 1998;83:1636-43
   PubMed Web of Science ®Google Scholar
• Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003;46:288-90
   PubMed Web of Science ®Google Scholar
• Page RL, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy 2003;23:945-54
   PubMed Web of Science ®Google Scholar
• Papoushek C. The “glitazones”: rosiglitazone and pioglitazone. J Obstet Gynaecol Can 2003;25:853-7
   PubMedGoogle Scholar
• Gim HJ, Cheon YJ, Ryu JH, Jeon R. Design and synthesis of benzoxazole containing indole analogs as peroxisome proliferator-activated receptor-gamma/delta dual agonists. Bioorg Med Chem Lett 2011;21:3057-61
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yano M, Miyake S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998;21:256-60
   PubMed Web of Science ®Google Scholar
• Shinozaki K, Suzuki M, Ikebuchi M, et al. Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 1996;45:731-7
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003;63:933-51
   PubMed Web of Science ®Google Scholar
• Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83:1515-22
   PubMed Web of Science ®Google Scholar
• Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993;46:1025-54
   PubMed Web of Science ®Google Scholar
• Santeusanio F, Compagnucci P. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus. Drug Saf 1994;11:432-44
   PubMed Web of Science ®Google Scholar
• Reuser AJ, Wisselaar HA. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 1994;24(3):19-24
   PubMedGoogle Scholar
• Geng P, Qiu F, Zhu Y, Bai G. Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of alpha-amylase. Carbohydr Res 2008;343:882-92
   PubMed Web of Science ®Google Scholar
• van Genugten RE, van Raalte DH, Diamant M. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Res Clin Pract 2009;86(Suppl 1):S26-34
   PubMedGoogle Scholar
• Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7
   PubMed Web of Science ®Google Scholar
• Nikfar S, Abdollahi M, Salari P. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. J Pharm Pharm Sci 2012;15:1-30
   PubMed Web of Science ®Google Scholar
• Nauck MA, Baranov O, Ritzel RA, Meier JJ. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 2013; published online 9 Jun 2013; doi:10.1007/s00125-013-2953-6
   Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39
   PubMed Web of Science ®Google Scholar
• Pospisilik JA, Stafford SG, Demuth HU, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002;51:943-50
   PubMed Web of Science ®Google Scholar
• Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther 2012;135(3):247-78
   PubMed Web of Science ®Google Scholar
• Siu FY, He M, de Graaf C, et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 2013;499(7459):444-9
   PubMed Web of Science ®Google Scholar
• Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011;34(Suppl 2):S279-84
   PubMed Web of Science ®Google Scholar
• Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl Univ Med Cent) 2006;19:281-4
   PubMedGoogle Scholar
• Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583-9
   PubMed Web of Science ®Google Scholar
• Bjerre KL, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86
   PubMed Web of Science ®Google Scholar
• Franks AS, Lee PH, George CM. Pancreatitis: a potential complication of liraglutide? Ann Pharmacother 2012;46:1547-53
   PubMed Web of Science ®Google Scholar
• Wajcberg E, Amarah A. Liraglutide in the management of type 2 diabetes. Drug Des Devel Ther 2010;4:279-90
   PubMed Web of Science ®Google Scholar
• Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:5025-37
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opin Investig Drugs 2011;20:723-32
   PubMed Web of Science ®Google Scholar
• Saisho Y, Itoh H. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? Diabet Med 2013;30:149-50
   PubMed Web of Science ®Google Scholar
• Zhu L, Li Y, Qiu L, et al. Design and synthesis of 4-(2,4,5-Trifluorophenyl)butane-1,3-diamines as Dipeptidyl Peptidase IV Inhibitors. ChemMedChem 2013;8:1104-16
   PubMed Web of Science ®Google Scholar
• Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512
   PubMed Web of Science ®Google Scholar
• Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
   PubMedGoogle Scholar
• Someya Y, Tahara A, Nakano R, et al. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 2008;377:209-17
   PubMed Web of Science ®Google Scholar
• Gupta R, Walunj SS, Tokala RK, et al. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets 2009;10:71-87
   PubMed Web of Science ®Google Scholar
• Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf 2013;12(4):545-57
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94
   PubMed Web of Science ®Google Scholar
• Babu A. Canagliflozin for the treatment of type 2 diabetes. Drugs Today (Barc) 2013;49:363-76
   PubMed Web of Science ®Google Scholar
• Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol 2012;52:457-63
   PubMed Web of Science ®Google Scholar
• Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;27:136-42
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-34
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-85
   PubMed Web of Science ®Google Scholar
• Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs 2013;73:979-88
   PubMed Web of Science ®Google Scholar
• Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2011;2:133-45
   PubMedGoogle Scholar
• Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53:6355-60
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-83
   PubMed Web of Science ®Google Scholar
• Keche Y. Bromocriptine mesylate: food and Drug Administration approved new approach in therapy of non-insulin dependent diabetes mellitus with poor glycemic control. J Pharm Bioallied Sci 2010;2:148-50
   PubMedGoogle Scholar
• Kumar KA, Kumar SP, Janardan S. Bromocriptine: a novel approach for management of type 2 diabetes mellitus. JDDT 2012;2:151-5
   Google Scholar
• Via MA, Chandra H, Araki T, et al. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes 2010;3:43-8
   PubMedGoogle Scholar
• Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;3:159-65
   PubMedGoogle Scholar
• Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 2008;117:574-84
   PubMed Web of Science ®Google Scholar
• Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins 2007;66:160-71
   PubMed Web of Science ®Google Scholar
• Edmondson SD, Mastracchio A, Duffy JL, et al. Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2005;15:3048-52
   PubMed Web of Science ®Google Scholar
• Xu J, Wei L, Mathvink R, et al. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2005;15:2533-6
   PubMed Web of Science ®Google Scholar
• Duffy JL, Kirk BA, Wang L, et al. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett 2007;17:2879-85
   PubMed Web of Science ®Google Scholar
• Chen P, Caldwell CG, Mathvink RJ, et al. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Bioorg Med Chem Lett 2007;17:5853-7
   PubMed Web of Science ®Google Scholar
• Cho TP, Gang LZ, Long YF, et al. Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2010;20:3521-5
   PubMed Web of Science ®Google Scholar
• Furuta S, Smart C, Hackett A, et al. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica 2013;43:432-42
   PubMed Web of Science ®Google Scholar
• Kato N, Oka M, Murase T, et al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 2011;19:7221-7
   PubMed Web of Science ®Google Scholar
• Yoshida T, Akahoshi F, Sakashita H, et al. Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group. Bioorg Med Chem 2012;20:5033-41
   PubMed Web of Science ®Google Scholar
• Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013;434:191-6
   PubMed Web of Science ®Google Scholar
• Magnin DR, Robl JA, Sulsky RB, et al. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors. J Med Chem 2004;47:2587-98
   PubMed Web of Science ®Google Scholar
• Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem 2012;20:5705-19
   PubMed Web of Science ®Google Scholar
• Sakashita H, Akahoshi F, Kitajima H, et al. [(S)-gamma-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors. Bioorg Med Chem 2006;14:3662-71
   PubMed Web of Science ®Google Scholar
• Sakashita H, Akahoshi F, Yoshida T, et al. Lead optimization of [(S)-gamma-(arylamino)prolyl]thiazolidine focused on gamma-substituent: indoline compounds as potent DPP-IV inhibitors. Bioorg Med Chem 2007;15:641-55
   PubMed Web of Science ®Google Scholar
• Yoshida T, Sakashita H, Akahoshi F, Hayashi Y. [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. Bioorg Med Chem Lett 2007;17:2618-21
   PubMed Web of Science ®Google Scholar
• Cox JM, Harper B, Mastracchio A, et al. Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007;17:4579-83
   PubMed Web of Science ®Google Scholar
• Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007;50:6450-3
   PubMed Web of Science ®Google Scholar
• Eckhardt M, Hauel N, Himmelsbach F, et al. 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg Med Chem Lett 2008;18:3158-62
   PubMed Web of Science ®Google Scholar
• Brigance RP, Meng W, Fura A, et al. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. Bioorg Med Chem Lett 2010;20:4395-8
   PubMed Web of Science ®Google Scholar
• Parmee ER, He J, Mastracchio A, et al. 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004;14:43-6
   PubMed Web of Science ®Google Scholar
• Chen P, Caldwell CG, Ashton W, et al. Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors. Bioorg Med Chem Lett 2011;21:1880-6
   PubMed Web of Science ®Google Scholar
• Maezaki H, Banno Y, Miyamoto Y, et al. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554. Bioorg Med Chem 2011;19:4482-98
   PubMed Web of Science ®Google Scholar
• Ikuma Y, Hochigai H, Kimura H, et al. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Bioorg Med Chem 2012;20:5864-83
   PubMed Web of Science ®Google Scholar
• Kinne RK, Castaneda F. SGLT inhibitors as new therapeutic tools in the treatment of diabetes. Handb Exp Pharmacol 2011(203):105-26
   PubMedGoogle Scholar
• Kipp H, Kinne-Saffran E, Bevan C, Kinne RK. Characteristics of renal Na(+)-D-glucose cotransport in the skate (Raja erinacea) and shark (Squalus acanthias). Am J Physiol 1997;273:R134-42
   PubMed Web of Science ®Google Scholar
• Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 2013;139:51-9
   PubMed Web of Science ®Google Scholar
• Isaji M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl 2011;S14-19
   PubMedGoogle Scholar
• Imamura M, Nakanishi K, Suzuki T, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 2012;20:3263-79
   PubMed Web of Science ®Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-9
   PubMed Web of Science ®Google Scholar
• Chen ZH, Wang RW, Qing FL. Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs. Tetrahedron Lett 2012;53:2171-6
   Web of Science ®Google Scholar
• Yao CH, Song JS, Chen CT, et al. Discovery of novel N-beta-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J Med Chem 2011;54:166-78
   PubMed Web of Science ®Google Scholar
• Yao CH, Song JS, Chen CT, et al. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors. Eur J Med Chem 2012;55:32-8
   PubMed Web of Science ®Google Scholar
• Ikegai K, Imamura M, Suzuki T, et al. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543. Bioorg Med Chem 2013;21:3934-48
   PubMed Web of Science ®Google Scholar
• Chen CH, Lee O, Yao CN, et al. Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2010;20:6129-32
   PubMed Web of Science ®Google Scholar
• Rekka E, Chrysselis M, Siskou I, Kourounakis A. Synthesis of new azulene derivatives and study of their effect on lipid peroxidation and lipoxygenase activity. Chem Pharm Bull (Tokyo) 2002;50:904-7
   PubMed Web of Science ®Google Scholar
• Zhang LY, Yang F, Shi WQ, et al. Synthesis and antigastric ulcer activity of novel 5-isoproyl-3,8-dimethylazulene derivatives. Bioorg Med Chem Lett 2011;21:5722-5
   PubMed Web of Science ®Google Scholar
• Mascitti V, Maurer TS, Robinson RP, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem 2011;54:2952-60
   PubMed Web of Science ®Google Scholar
• Mascitti V, Robinson RP, Préville C, et al. Syntheses of C-5-spirocyclic. C-glycoside SGLT2 inhibitors. Tetrahedron Lett 2010;51:1880-3
   Web of Science ®Google Scholar
• Vyas VK, Bhatt HG, Patel PK, et al. CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents. SAR QSAR Environ Res 2013;24:519-51
   PubMed Web of Science ®Google Scholar
• Wu JS, Peng YH, Wu JM, et al. Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening. J Med Chem 2010;53:8770-4
   PubMed Web of Science ®Google Scholar
• Sheridan C. SGLT2 inhibitors race to enter type-2 diabetes market. Nat Biotechnol 2012;30:899-900
   PubMed Web of Science ®Google Scholar
• Shing TK, Ng WL, Chan JY, Lau CB. Design, syntheses, and sar studies of carbocyclic analogues of sergliflozin as potent sodium-dependent glucose cotransporter 2 inhibitors. Chem Int Ed Engl 2013; published online 19 Jun 2013; doi:10.1002/anie.201302543
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhao G, Liu W, et al. Thiadiazole-based thioglycosides as sodium-glucose co-transporter 2 (sglt2) inhibitors. Chin J Chem 2010;28:605-12
   Web of Science ®Google Scholar
• Liao C, Sitzmann M, Pugliese A, Nicklaus MC. Software and resources for computational medicinal chemistry. Future Med Chem 2011;3:1057-85
   PubMed Web of Science ®Google Scholar
• Liu L, Ma Y, Wang RL, et al. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics. Drug Des Devel Ther 2013;7:279-88
   PubMed Web of Science ®Google Scholar
• Kitada M, Kume S, Kanasaki K, et al. Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets 2013;14:622-36
   PubMed Web of Science ®Google Scholar
• Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712-16
   PubMed Web of Science ®Google Scholar
• Kun S, Nagy GZ, Toth M, et al. Synthesis of variously coupled conjugates of D-glucose, 1,3,4-oxadiazole, and 1,2,3-triazole for inhibition of glycogen phosphorylase. Carbohydr Res 2011;346:1427-38
   PubMed Web of Science ®Google Scholar
• Panzhinskiy E, Ren J, Nair S. Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus. Curr Med Chem 2013;20:2609-25
   PubMed Web of Science ®Google Scholar
• Patel D, Jain M, Shah SR, et al. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors. Bioorg Med Chem Lett 2012;22:1111-17
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7
   PubMed Web of Science ®Google Scholar
• Becic F, Kapic E, Becic E. Glimepiride–an oral antidiabetic agent. Med Arh 2003;57:125-7
   PubMedGoogle Scholar
• Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988;35:214-43
   PubMed Web of Science ®Google Scholar
• Madsbad S. Liraglutide effect and action in diabetes (LEAD™) trial. Expert Rev Endocrinol Metab 2009;4:119-29
   PubMedGoogle Scholar
• Panina G. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. Diabetes Obes Metab 2007;9:32-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
   PubMed Web of Science ®Google Scholar
• Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009;26:249-62
   PubMed Web of Science ®Google Scholar
• Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-51
   PubMed Web of Science ®Google Scholar
• Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89
   PubMed Web of Science ®Google Scholar
• Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-300
   PubMed Web of Science ®Google Scholar
• Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-82
   PubMed Web of Science ®Google Scholar
• Metzler WJ, Yanchunas J, Weigelt C, et al. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Protein Sci 2008;17:240-50
   PubMed Web of Science ®Google Scholar
• Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320:323-30
   PubMed Web of Science ®Google Scholar